MP24-17 TAMSULOSIN VERSUS TADALAFIL FOR MANAGEMENT OF SYMPTOMATIC BENIGN PROSTATIC ENLARGEMENT: ASSESSMENT OF TREATMENT DISCONTINUATION RATE AND SYMPTOMS IMPROVEMENT

Abstract

You have accessJournal of UrologyCME1 Apr 2023MP24-17 TAMSULOSIN VERSUS TADALAFIL FOR MANAGEMENT OF SYMPTOMATIC BENIGN PROSTATIC ENLARGEMENT: ASSESSMENT OF TREATMENT DISCONTINUATION RATE AND SYMPTOMS IMPROVEMENT Ahmed Elqaffas, Ahmed Elshal, Adel Nabeeh, and Ahmed M Shoma Ahmed ElqaffasAhmed Elqaffas More articles by this author , Ahmed ElshalAhmed Elshal More articles by this author , Adel NabeehAdel Nabeeh More articles by this author , and Ahmed M ShomaAhmed M Shoma More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003249.17AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: both tamsulosin and tadalafil 5 mg are used for treatment of symptomatic benign prostatic enlargement. Nevertheless, the incidence and causes of treatment discontinuation (TD) was not evaluated. A randomized trial is conducted to compare TD rate and symptoms improvement between the two drugs. METHODS: A randomized controlled trial (RCT) is conducted with estimate sample size of 160 cases. Sexually active LUTS/BPO patients with concomitant ED were included and randomly allocated in two groups: the first received tadalafil 5 mg once daily and the second one received tamsulosin for twelve months. The therapeutic outcomes are assessed at 2 weeks , 4 weeks , 12 weeks, 6 months and 12 months. The evaluation includes International Prostate Symptom Score (IPSS), International Index of Erectile Function (IIEF-15) questionnaire, quality of life (QoL), uroflowmetry, post voiding residual (PVR) and incidence and causes of (TD). RESULTS: In tadalafil group 5 patients lost follow up. thirty out of 80 patients showed drug discontinuation (37.5%), 6 of them developed adverse effects in view of headache and musculoskeletal pain, other 24 patients developed no response. IPSS, QoL & IIEF-15 improved in 12 months follow-up compared to baseline criteria (Table 1). In tamsulosin group, 7 patients lost follow up. Eighteen out of 80 patients showed drug discontinuation (22.5%), 5 of them developed adverse effects in view of dizziness and orthostatic hypotension, while 13 patients showed no response. IPSS, QoL & Qmax improved in 12 months follow-up compared to baseline criteria. (Table 1) CONCLUSIONS: When both groups were compared, discontinuation was higher in tadalafil group due to lack of response with significant statistical difference with comparable adverse events. IPSS & QoL were improved in both drugs. Source of Funding: mansoura urology and nephrology center (UNC) © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e324 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Ahmed Elqaffas More articles by this author Ahmed Elshal More articles by this author Adel Nabeeh More articles by this author Ahmed M Shoma More articles by this author Expand All Advertisement PDF downloadLoading ...